Acadia Pharmaceuticals Inc (NASDAQ: ACAD) is -47.56% lower on its value in year-to-date trading and has touched a low of $14.55 and a high of $32.59 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ACAD stock was last observed hovering at around $16.33 in the last trading session, with the day’s gains setting it 0.09%.
Currently trading at $16.42, the stock is 2.09% and -2.69% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.78 million and changing 0.55% at the moment leaves the stock -17.96% off its SMA200. ACAD registered -32.82% loss for a year compared to 6-month loss of -12.00%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 5.46% gain in the last 1 month and extending the period to 3 months gives it a 11.32%, and is 2.95% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.86% over the week and 3.30% over the month.
Acadia Pharmaceuticals Inc (ACAD) has around 598 employees, a market worth around $2.72B and $890.53M in sales. Current P/E ratio is 91.99 and Fwd P/E is 18.97. Profit margin for the company is 3.43%. Distance from 52-week low is 12.85% and -49.62% from its 52-week high. The company has generated returns on investments over the last 12 months (5.42%).
Acadia Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at 0.14 with sales reaching $248.67M over the same period.The EPS is expected to grow by 250.04% this year, but quarterly earnings will post 31.10% year-over-year. Quarterly sales are estimated to grow 17.50% in year-over-year returns.
369.0 institutions hold shares in Acadia Pharmaceuticals Inc (ACAD), with institutional investors hold 100.56% of the company’s shares. The shares outstanding are 164.65M, and float is at 164.62M with Short Float at 6.24%. Institutions hold 100.02% of the Float.
The top institutional shareholder in the company is BAKER BROS. ADVISORS LP with over 42.88 million shares valued at $696.77 million. The investor’s holdings represent 26.0185 of the ACAD Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 13.71 million shares valued at $222.82 million to account for 8.3206 of the shares outstanding. The other top investors are RTW INVESTMENTS, LP which holds 13.71 million shares representing 8.3178 and valued at over $222.75 million, while BLACKROCK INC. holds 7.3194 of the shares totaling 12.06 million with a market value of $196.01 million.
Acadia Pharmaceuticals Inc (ACAD) Insider Activity
The most recent transaction is an insider sale by Schneyer Mark C., the company’s EVP, CHIEF FINANCIAL OFFICER. SEC filings show that Schneyer Mark C. sold 9,733 shares of the company’s common stock on Aug 19 ’24 at a price of $15.28 per share for a total of $0.15 million. Following the sale, the insider now owns 43735.0 shares.
Acadia Pharmaceuticals Inc disclosed in a document filed with the SEC on Aug 19 ’24 that Teehan Brendan (EVP, COO, HEAD OF COMMERCIAL) sold a total of 9,534 shares of the company’s common stock. The trade occurred on Aug 19 ’24 and was made at $15.28 per share for $0.15 million. Following the transaction, the insider now directly holds 52177.0 shares of the ACAD stock.
Still, SEC filings show that on Aug 19 ’24, DAVIS STEPHEN (CEO) disposed off 31,747 shares at an average price of $15.28 for $0.49 million. The insider now directly holds 186,555 shares of Acadia Pharmaceuticals Inc (ACAD).
